Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations

NCT02352844 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT02352844
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02352844 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Completed
Start date
October 7, 2015
Completion date
August 15, 2017
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid malignancy, solid tumor